Theralizumab was initially developed for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) and rheumatoid arthritis; it is a humanized monoclonal antibody that acts as a potent agonist by binding to the CD28 receptor on T cells of the immune system.